Inhibrx Biosciences Cash Flow Statement
NASDAQ: INBXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Inhibrx Biosciences free cash flow
In fiscal 2025, Inhibrx Biosciences generated -$129.8 million of operating cash flow and spent $31,000 on capital expenditures. That left free cash flow of -$129.8 million, a free-cash-flow margin of -9986.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Inhibrx Biosciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Net Income | -140.06M | 1.69B | -241.36M |
| Net Income growth (YoY) | -108.30% | — | — |
| Depreciation & Amortization | 2.48M | 2.29M | 1.19M |
| Stock-Based Compensation | 11.14M | 58.52M | 24.85M |
| Change in Working Capital | -6.06M | 56.58M | 17.19M |
| Operating Cash Flow | -129.79M | -194.41M | -193.31M |
| Capital Expenditures | -31.00K | -2.60M | -4.59M |
| Investing Cash Flow | -28.00K | -2.60M | -4.59M |
| Financing Cash Flow | 101.45M | 71.68M | 201.96M |
| Net Change in Cash | -28.38M | -125.33M | 4.06M |
| Free Cash Flow | -129.82M | -197.01M | -197.90M |
This table shows 3 annual periods of Inhibrx Biosciences's cash flow statement, from FY 2025 back to FY 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow INBX's reporting calendar. What is a cash flow statement?